Experimental Drug Successfully Reduces Double Chin in Studies

September 17, 2013

(Reuters) - Kythera Biopharmaceuticals Inc said its experimental injectable drug succeeded in reducing double chin of patients in late-stage studies, meeting the main and secondary goals of two clinical trials.

The company's shares jumped 10% on the positive data for its lead drug known as ATX-101.

Over 1000 patients with moderate to severe submental fat were tested in the two studies conducted in the United States and Canada, where ATX-101 was evaluated against a placebo.

If approved, the drug could fulfill an unmet medical need as there is no proven non-surgical option to effectively reduce submental fat, said Dr Jean Carruthers, one of the investigators of Kythera's clinical study.

The most common adverse events were swelling, pain, bruising, numbness and redness, but none were treatment-related, Kythera said.

Kythera, which focuses on making aesthetic medicines, will disclose additional data from the two studies at the American Society for Dermatologic Surgery meeting that gets underway October 3.

The company has said it plans to assess future potential treatments for ATX-101 in the body.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: